Background:Long COVID (LC) presents with complex pathophysiology,affecting multiple organs and producing a range of symptoms,from neuropsychiatric disturbances to multi-organ dysfunction.Liver damage has emerged as a notable feature,yet no systematic review or meta-analysis has comprehensively evaluated the biomarkers confirming liver injury in LC patients. Objective:The present study aims to examine blood-based biomarkers of liver damage in LC disease. Methods:A search of PubMed,Google Scholar, SciFinder,and SCOPUS identified 61 eligible studies,including 7172 participants,with 3404 LC patients and 3768 controls. Results:Our analysis identified a significant increase in the liver damage index among LC patients,with a moderate effect size (standardized mean difference,SMD = 0.553;confidence intervals; 95% CI: 0.305;0.760) compared to normal controls. Additionally,LC patients exhibited marked elevations in alanine aminotransferase(SMD = 0.615;95% CI:0.351;0.878), aspartate aminotransferase(SMD=0.352;95%CI:0.068;0.637), gamma-glutamyl transferase(SMD=0.969;95% CI:0.194;1.745), and lactate dehydrogenase (SMD = 0.666; 95% CI: 0.332;0.999) activities. Moreover, significant reductions were observed in total protein (SMD = -0.326; 95% CI: -0.631 to -0.021) and platelet count (SMD = -0.424; 95% CI: -0.756 to -0.091), alongside increases in prothrombin time (SMD = 0.633;95%CI:0.0771.189),ferritin(SMD=0.437;95% CI: 0.0690.805),Ddimer(SMD=0.359;95%CI:0.1440.573), and fibrinogen(SMD=1.063;95%CI:0.412;1.714). Conclusion:This study suggests that LC is associated with persistent liver damage and coagulopathy,highlighting the need to incorporate liver injury into treatment strategies to reduce potential risks.